FLX475 + ipilimumab

This drug is a **combination therapy** of FLX475 and ipilimumab, investigated specifically for **advanced melanoma** that has progressed after anti-PD-1 or anti-PD-L1 therapy. **FLX475** is an orally available small molecule antagonist of the C-C chemokine receptor 4 (CCR4), designed to block the recruitment of suppressive regulatory T cells (Treg) into tumors, thereby enhancing the anti-tumor immune response. **Ipilimumab** is a monoclonal antibody and immune checkpoint inhibitor targeting cytotoxic T-lymphocyte-associated protein 4 (CTLA-4), thereby promoting T cell-mediated anti-tumor responses. The combination aims to synergistically enhance anti-tumor immunotherapy efficacy by both relieving immune suppression (via FLX475's CCR4 antagonism) and promoting T cell activation (via CTLA-4 blockade by ipilimumab). The combination is under investigation in a Phase 2 open-label clinical trial. FLX475 is developed by RAPT Therapeutics. Ipilimumab (Yervoy) was developed by Bristol Myers Squibb.

Brand names

Yervoy

Other names

FLX475 + Yervoy